Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.57 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28457278 | 0.88 | PPARA (0.55) | S1PR1S1PR5PPARAFFAR4FFAR1 | |
| SCHEMBL7792665 | 0.87 | FFAR1 (0.51) | S1PR1S1PR5PPARAFFAR4FFAR1 | |
| SCHEMBL2127169 | 0.85 | GAA (0.62) | RXRARXRBRXRGPTGDR2 | |
| SCHEMBL3490898 | 0.83 | GAA (0.50) | S1PR1S1PR5PPARAPPARD | |
| SCHEMBL7794917 | 0.83 | FFAR1 (0.48) | S1PR1S1PR5PPARAFFAR4FFAR1 | |
| SCHEMBL7792671 | 0.82 | FFAR1 (0.47) | S1PR1S1PR5PPARAFFAR4FFAR1 | |
| SCHEMBL347209 | 0.81 | FFAR4 (0.61) | FFAR4FFAR1 | |
| SCHEMBL13665426 | 0.80 | S1PR1 (0.65) | S1PR1S1PR5FFAR4FFAR1FFAR2 | |
| SCHEMBL22630207 | 0.80 | FFAR1 (0.56) | S1PR1S1PR5FFAR4FFAR1FFAR2 | |
| SCHEMBL585819 | 0.80 | FFAR4 (0.60) | PPARAFFAR4FFAR1FFAR2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | S1PR1 1700/4885S1PR5 2181/4885PPARA 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.